Evercore ISI added Boston Scientific (BSX) to the firm’s “Tactical Outperform” list while keeping an Outperform rating on the shares with a $96 price target The company this weekend will be presenting data on its CHAMPION-AF and HI-PIETHO cardiovascular trials, the analyst tells investors in a research note. Evercore is positive that the CHAMPION-AF readout will provide a catalyst for shares into the second half of 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific’s Agent DCB: Strong Early Adoption and Underappreciated Multiyear Growth Opportunity
- Boston Scientific price target lowered to $90 from $110 at Stifel
- Boston Scientific: Limited Financial Fallout From Pacemaker Recalls Supports Continued Buy Rating
- FDA inspectors found Boston Scientific pacemakers had battery issues, NYT says
- IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Diversification and Growth to Investors